Important Information for Regeneron Pharmaceuticals Investors: Rosen Law Firm Reminds of Upcoming Deadline
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023, and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. This deadline applies to those who may have purchased or acquired Regeneron securities during the Class Period and may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What Happened to Regeneron Pharmaceuticals?
During the Class Period, Regeneron Pharmaceuticals, Inc. (Regeneron) announced positive results from its clinical trials for its drug, Evkeeza, which is used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that causes high levels of LDL-C, or “bad cholesterol.” Regeneron’s stock price saw significant increases following these announcements.
Why Should Regeneron Investors Care?
According to the lawsuit, during the Class Period, Regeneron made false and/or misleading statements and/or failed to disclose: (1) that the clinical trial data for Evkeeza was falsely reported; (2) that the drug’s clinical trial results did not meet the primary endpoint for the study’s main goal; and (3) that the drug’s safety and efficacy were under regulatory scrutiny.
What Does This Mean for Regeneron Investors?
If you purchased Regeneron securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline, which is an important deadline for potential lead plaintiffs, is fast approaching. If you wish to serve as lead plaintiff, you must move quickly. To be eligible for compensation, you need not take any action at this time. Your ability to share in any recovery doesn’t require you to be the lead plaintiff.
How Will This Impact the World?
The implications of this lawsuit extend beyond just Regeneron investors. If the allegations in the lawsuit are proven true, it could potentially impact the credibility of the company and the biotechnology industry as a whole. It also highlights the importance of transparency and honest reporting in the pharmaceutical industry, as well as the role of regulatory bodies in ensuring the safety and efficacy of drugs.
Conclusion
If you purchased Regeneron securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is March 10, 2025. Rosen Law Firm encourages investors to contact them for more information about the class action and how they can potentially recover their losses. The potential impact of this lawsuit goes beyond just Regeneron investors, as it highlights the importance of transparency and honest reporting in the pharmaceutical industry and the role of regulatory bodies in ensuring the safety and efficacy of drugs.
- If you purchased Regeneron securities during the Class Period, you may be entitled to compensation.
- The lead plaintiff deadline is March 10, 2025.
- Contact Rosen Law Firm for more information about the class action and how to potentially recover losses.
- This lawsuit has implications beyond just Regeneron investors, as it highlights the importance of transparency and honest reporting in the pharmaceutical industry and the role of regulatory bodies in ensuring drug safety and efficacy.
